Combining network pharmacology and in vitro and in vivo experiments to study the mechanism of Keluoxin in the treatment of radiation nephropathy

Author:

Deng Lin1,Wang Shaoqing1,Leng Xingli1,Yao Peng1,Li Cuicui2,Zheng Yang3

Affiliation:

1. Nephrology Department of The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital , Chengdu, China, No. 4, North Section 4, Second Ring Road, Chengdu 610057 , China

2. Physical Examination Center of General Hospital of Western Warzone , China, No. 270 Tianhui Road, Rongdu Avenue, Chengdu, Sichuan Province 610083 , China

3. Nephrology Department of The Second Affiliated Hospital of Chengdu Medical College , China National Nuclear Corporation 416 Hospital, Chengdu, China, No. 4, North Section 4, Second Ring Road, Chengdu 610057 , China

Abstract

Abstract Radiation nephropathy refers to kidney damage caused by radiation therapy for malignant tumours. Currently, the pathogenesis is unclear and there is a lack of effective treatment methods. With the development of traditional Chinese medicine, the role of traditional Chinese medicine in the protection of radiation nephropathy is receiving increasing attention. Therefore, in this study, we used X-ray intraperitoneal irradiation to construct a mouse model of radiation nephropathy and studied the protective effect of traditional Chinese medicine Keluoxin on radiation nephropathy. We first analysed the potential targets and pathways of Keluoxin in the treatment of radiation nephropathy using network pharmacology methods, combined with in vitro and in vivo experimental verification, to study its potential mechanism. By searching the database, 136 components of Keluoxin were identified. A total of 333 intersectional targets related to radiation nephropathy were obtained. Among them, key targets include IL-6, TNF-α, HIF-1α, STAT1, STAT3, JAK1, JAK2, etc. In in vivo and in vitro experiments, we found that as the irradiation dose increased and time prolonged, kidney damage in mice gradually worsened in a time-dependent and dose-dependent manner. As the irradiation dose increases, the expression of pro-inflammatory factors Il-6, TNF-α, TGF-β increased. Compared with the irradiation group, the intervention of Keluoxin can reduce kidney damage caused by X-ray irradiation and reduce the expression of IL-6, TNF-α, TGF-β, STAT1, STAT3, JAK1, JAK2, etc. These results indicated that Keluoxin can alleviate kidney damage caused by X-ray irradiation, possibly by regulating the JAK/STAT signalling pathway, reducing inflammation levels and oxidative stress damage.

Funder

Key Projects of the Nuclear Medicine Science and Technology Innovation

Scientific Research Project of Traditional Chinese Medicine of Sichuan Administration of Traditional Chinese Medicine

Medical Research Project of Medical Health Public Welfare Foundation of Beijing

Publisher

Oxford University Press (OUP)

Subject

Health, Toxicology and Mutagenesis,Radiology, Nuclear Medicine and imaging,Radiation

Reference41 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology;Bentzen;Nat Rev Cancer,2006

3. Pay attention to prevention and treatment of acute renal injury caused by ionizing radiation;Aihua Guo;Chin J Blood Purif,2019

4. Cancer treatment and survivorship statistics, 2022;Miller;CA Cancer J Clin,2022

5. Clinical aspects of radiation nephropathy;Breitz;Cancer Biother Radiopharm,2004

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3